Traverse Biosciences and the Stony Brook University School of Dental Medicine have received a $1.3 million award from the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health (NIH) to further evaluate the pre-clinical safety and effectiveness of the Traverse Biosciences’ leading drug candidate,
Learn MoreiCell Gene Therapeutics, a CFB client company, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL).
Learn MoreThe Center for Biotechnology is thrilled to present our newly designed newsletter.
Learn MoreCodagenix has announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the United States Department of Agriculture (USDA) to commence the development of an influenza vaccine for swine.
Learn MoreOrtek Therapeutics announced that the U.S. Patent and Trademark Office has awarded a patent for new methods to use new compositions to prevent or treat drug-resistant bacteria and suppress body odor.
Learn MoreTraverse Biosciences has announced a collaboration with SUNY Updated Medical University on a Peer Reviewed Medical Research Program (PRMRP) Discovery Award from the U.S. Department of Defense.
Learn More